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Cyclic-di-GMP is a second messenger in bacteria and is involved in signal 
transduction pathways. This molecule has been shown to bind to the GGDEF, EAL 
and HD-GYP domain containing proteins, regulating a variety of bacterial functions. 
Diguanylate cyclases (DGCs) have the GGDEF domain that catalyzes the formation 
of cyclic-di-GMP from two GTP molecules. Experimental studies of cyclic-di-GMP 
pathways and development of anti-virulence agents necessitate milligram quantities of 
c-di-GMP. Since chemical synthesis of cyclic-di-GMP is time-consuming and 
expensive, an enzymatic approach, using enzymes such as PleD and WspR, is being 
used to produce cyclic-di-GMP on a laboratory scale. However, these enzymes yield 
significantly low amounts of cyclic-di-GMP due to poor thermostability and strong 
product inhibition. Furthermore, the produced cyclic-di-GMP mediates feedback 
inhibition by binding to a conserved motif , called I site, in the enzyme. The Liang lab 
of NTU university have reported a stand-alone GGDEF domain from Thermotoga 
maritima with a mutation at the inhibitory site (R158A) which is devoid of any 
feedback inhibition and synthesizes milligram quantities of cyclic-di-GMP. This 
mutant also exhibits a good half-life due to improved thermostability. Although 
recently mesophilic enzymes with mutation at the I site have been used, the use of a 
thermostable enzyme is advantageous as it remains active at room temperature for 
several days enabling continuous synthesis. This current study involves the structural 
characterization of the standalone GGDEF domain DGC from this thermophile. The 
GGDEF domain has been crystallized in an inhibited conformation with cyclic-di-
GMP bound at the inhibitory site, mediating dimer formation. The bridging of the two 




by domain immobilization, where the active sites are pushed apart forming an inactive 
conformation as observed in homologous structures. Also, the structure of the apo 
form of the I site mutant (R158A) has been solved at 2.5 Å resolution. A third crystal 
form in an active-like dimeric conformation with the active sited in proximity was 
used to develop a model of the catalytically active dimer. Comparison of the GGDEF 
domains with and without the ligand, suggests that the overall structure is similar and 
binding of dimeric ligand at the I site creates no changes at the active site indicating 
an absence of intrinsic allostery. Additionally, a comparison of the electrostatic 
interactions, hydrogen bonds and other parameters known to contribute to 
thermostability indicated that the higher thermostability of this enzyme is solely due 
to the large network of ion pairs. This was also verified by thermal denaturation 
experiments, which suggested that salt bridge forming residues at loop regions 
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1. X-RAY CRYSTALLOGRAPHY 
 
1.1  INTRODUCTION 
Visualization of protein molecules at the atomic or near atomic level is 
achieved by techniques such as X-ray crystallography, Nuclear Magnetic Resonance 
(NMR) and Electron Microscopy (EM). Of these, X-ray crystallography has been in 
use for over 80 years to determine the structures of small molecules and chemical 
structures in their crystalline states. The first protein structure solved by this technique 
was that of myoglobin in 1960 (Kendrew, Dickerson et al. 1960). This method holds 
the key to understanding how proteins work, characterizing their conformational 
changes and interaction with other proteins. 
 
1.2  CRYSTALLIZATION OF PROTEINS 
Analysis of protein structures by this technique requires a crystalline form of 
the sample; hence crystallization is the rate-limiting step in this process. Crystals are 
grown from a state of supersaturation which can be achieved by various methods, one 
of which is vapor diffusion. As the super-saturated protein solution returns to 
equilibrium, due to thermodynamic requirements of reducing Gibbs free energy, 
water molecules are excluded, forcing the arrangement of molecules into an ordered 
lattice, a requirement for good diffraction (Helliwell 2005). 
Crystallization is usually performed by vapor diffusion in which a protein 
solution is mixed with a precipitating agent and allowed to equilibrate in a closed 
environment with a reservoir solution at a concentration ideal for producing crystals. 
Typical precipitating agents used for the growth of crystals are salts, organic solvents, 







Figure 1.1. Crystallization Phase Diagram. The pink region shows 
concentration of protein and precipitant that are neither suitable for 
nucleation nor for growth. Ideally, the protein must be moved to the 
blue region to allow nucleation and gradually moved to green area to 
facilitate growth (Rhodes 2006).  
 
 
1.3  UNIT-CELL AND SYMMETRY 
Protein molecule in a crystalline state obey an ordered three-dimensional 
array, defined by a set of geometrical parameters that explain the periodicity and 
disposition of its basic units, called unit-cell. A unit-cell is defined by six parameters 
– the lengths of the three unique edges a, b and c and three unique interaxial angles α, 
β, and γ. 
 





The basic symmetry elements that arrange molecules in a crystal are inversion, 
reflection and rotation.  A fundamental volume, called the asymmetric unit, is chosen 
such that this unit is repeated by crystallographic symmetry to form equivalent parts 
in a unit-cell.  Thus, an entire crystal is created from an asymmetric unit by applying a 
sequence of symmetry operations, including unit-cell translation.  
Unit-cells are the basic units that give rise to lattices with one unit-cell 
representing one lattice point. There are seven different types of crystal systems, 
which constitute the 14 Bravais lattices, named after the physicist Auguste Bravais 
who first proposed their existence in 1845. Fig. 1.3 shows the types of unit-cell 
lattices that are the allowable for each crystal system. Primitive unit-cell (P) contains 
one lattice point, with one eight of a point contributed by each point at the corners of 
the unit-cell. Face-centered (C) and body-centered (I) unit-cells contain two lattice 





Figure 1.3. Types of Crystal Systems. Based on the unit-cell 
parameters that support different symmetries, the crystal systems can 
be classified into seven groups.  Adapted from - 
http://www.iue.tuwien.ac.at/phd/karlowatz/node8.html 
 
1.3.1  Planes in a crystal  
A crystal can be imagined to be sliced into planes. These imaginary planes are 
identified by the Miller indices h, k and l, (Fig. 1.4), that determine the number of 
planes in the unit-cell direction a, b, c, respectively. . Thus, the index h gives the 
number of planes in the unit-cell in the x direction or the number of parts into which 










1.4  WAVES AND THEIR PROPERTIES 
W.L Bragg showed that for a set of parallel planes hkl with interplanar 
distance dhkl, incident X-rays with wavelength λ at an incident angle θ is reflected at 
the same angle θ only when the following condition is satisfied 
  2 dhkl  sinθ = nλ    Equation (1) 
 
Figure 1.5. Bragg’s Law. Rays R1 and R2 undergo constructive 
interference if the extra distance travelled by R2 is an integral multiple 
of the wavelength (Rhodes 2006). 
 
According to Braggs’ law rays R1 and R2 interfere constructively and produce 




multiple of wavelength. When a monochromatic beam of X-rays is directed onto a 
crystal, the set of planes that satisfy Bragg’s law give rise to constructive interference 
and thereby produce diffracted X-rays. 
 
1.4.1  Bragg’s law in reciprocal space 
  A reciprocal lattice is constructed by normals (perpendiculars) to Miller 
planes. This concept was postulated by Ewald. 
 
Figure 1.6. Ewald’s sphere in reciprocal space. As the crystal is 
rotated, all the lattice points that lie on the circle of radius 1/λ produce 
diffraction. 
 
Fig. 1.6 is  called the Ewald sphere, constructed in reciprocal space with a radius of 
1/λ, with O as the centre of the reciprocal lattice and B is a point (h,k,l) and distance 
OB is 1/dhkl, then  
   sin θ  =  OB / 2r 
   sin θ  =  ( 1/dhkl ) / (2 / λ )  
i.e, λ = 2 dhkl sin θ   Equation (2) 
Thus, when a crystal is rotated, about origin O, all the reciprocal lattice points that lie 






Figure 1.7. Ewald’s sphere of reflection. As the reciprocal lattice 
point 012 lies on the sphere it produces reflection R 012 (Rhodes 
2006). 
   
1.5  POINT GROUPS AND SPACE GROUPS 
The allowed combinations of the three basic symmetry operations (rotation, 
inversion and reflection) in the seven crystal systems are called point groups. There 
are 32 unique point groups. The basic symmetry operations and their possible 
derivative symmetry operations screw axes and glide planes, when combined with the 
14 Bravais lattices, produce 230 space groups that describe the way in which 
molecules are arranged in a crystal (Buerger 1971). Note that a screw axis is the 
combination of rotation and translation parallel to the rotation axis and a glide plane 
results from reflection and translation along or diagonal to the unit-cell axes that 
define the reflecting plane. Since inversion and reflection symmetry elements are not 
possible in proteins, the number of space groups in macromolecules is only 65 (Hahn 
2002).  
 
1.6  X-RAY DIFFRACTION 
When a crystal is exposed to an X-ray beam, for a specific orientation, one or 
a set of parallel hkl planes will be in diffracting position and produces diffraction 
intensity. As a crystal is rotated, the intensities of diffraction by most, if not all, 




space) is related to the atomic arrangement in a crystal (real space) by Fourier 
transform.  
 
1.6.1  Crystal symmetry and systematic absences 
 The existence of screw axis and glide planes in a crystal can be determined 
from the systematically absence of certain classes of reflection. These absences fall 
along axial reflections (h00, 0k0, 00l) for screw axis, and 0kl, h0l and hk0 reflections 
for glide planes.  
 
1.7  STRUCTURE FACTOR 
Each reflection is the result of the diffraction sum of all atoms (scatterers) in 
the unit cell. This summation effect is called structure factor. For a reflection from the 
plane hkl, Fhkl is the structure factor, which is the summation of the scattering of every 
atom in the unit-cell. In fact, the actual contributors to scattering are the clouds of 
electrons in the unit-cell.  Hence the structure factor is a summation of scattering 
contributed by electron density within the unit-cell. In practice, for a unit-cell with n 
atoms, the structure factor Fhkl is the sum of all the scattering factors of each atom (fj). 
The scattering factor decays rapidly with increase in the diffraction angle. 
 ∫ ∫ ∫ ++=
h k l
lzkyhxi dxdydzezyxflkhF )(2),,(),,( π          Equation (3) 
In the above equation, f is the scattering factor and (x,  y, z) represents the coordinates 
of an atom in the unit-cell. 
With the help of Bragg’s law and the geometry of the diffraction experiment 
setup, we can deduce the hkl index for each spot on the detector. This way, once the 




electron density elements in the unit-cell. To obtain the molecular details, each 
reflection is deconvoluted into scattering by atoms. This is achieved mathematically 
by considering each reflection as a complex number. 
 
1.7.1  Structure factors as complex numbers 
A reflection can be described as a structure factor, which is a Fourier 
summation of contribution from every volume element of the unit-cell. Fhkl can be 
considered as a complex number where, as shown in the figure below, the scalar 
component |Fhkl| or the intensity of reflection is known but the position of the atom or 
the phase Φhkl is unknown. 
 
Figure 1.8. Structure Factors as Complex Numbers. A wave can be 
represented as a complex number, the amplitude represented as the 
radius and Φhkl as the phase angle of the wave. 
 
1.7.2  Friedel’s law 
Friedel’s law states that the structure factors of the h,k,l and –h,-k,-l family of 
planes are the same. These reflections have the same amplitude, but opposite phase. 
Hence, the diffraction pattern has a center of symmetry i.e., the reflections of equal 
intensity are related by inversion through the origin. However, the amplitudes do not 







Figure 1.9. Vector representation of Friedel Pairs Representation of 
structure factors from equivalent planes and opposite phases. Adapted 
from - http://skuld.bmsc.washington.edu/scatter/AS_Friedel.html 
 
1.8  CRYSTALS AS WAVES OF ELECTRONS 
A crystal can be considered as a three dimensional function in space with one 
unit-cell translation as the period of the wave and the value of the function at any 
point x, y ,z as the electron density at that point ρ(x, y ,z).  So, similar to a wave 
function, the electron density can be broken down into its spectral components that 








 Electron density can be represented as a Fourier sum of the structure factors 
from each set of planes. Just as the structure factor is contributed by waves from all 
the atoms in the unit-cell, the electron density includes all structure factors. 
 
1.8.1  The phase problem 
To calculate the electron density at any point, the variable Fhkl is required. Fhkl 
is a complex number with amplitude and phase. A detector can determine the 




cannot be measured experimentally. This is infamously known as the phase problem 
in crystallography, which is overcome by using various techniques explained later. 
 
1.9  PROCESSING X-RAY DATA 
 Data collection involves recording a number of diffraction images at various 
orientations of the crystal with each image having more than hundred reflections. In 
order to assign the intensities of reflections, it is required to fit the geometric position 
of every refection to a point in the reciprocal lattice. This process, known as indexing, 
assigns the hkl triplet to every reflection. The initial indexing is performed with a 
single image, which requires information of various parameters some of which are the 
wavelength, crystal to detector distance, position of the beam and oscillation angle. 
Using these parameters the unit-cell parameters and the angles defining crystal 
orientation are determined. 
 Once the appropriate space group is selected, the lattice parameters are refined 
by correcting for systemic errors such as absorption due to non-regular crystal 
morphology, non-linearity in monitoring the incident beam intensity and changes in 
the average diffracted intensities arising from variation in the total diffracting volume 
of the crystal. Also, the thermal vibration of atoms and radiation damage, which 
increases as a function of resolution, are accounted for (Ravelli and Garman, 2006). 
Multiple observations of symmetry related reflections are averaged to give accurate 
values of unique reflections (the minimum number of reflections needed for structure 
determination) 
 A parameter that is used to gauge data quality is Rsym, It measures the extent to 
which equivalent reflections deviate from each other.  





Ii(hkl) is the scaled observed intensity and <I (hkl) > is the mean value of 
corresponding symmetry-related reflections. Rsym is used when scaling within the 
same dataset and Rmerge represents the data quality when multiple datasets are merged. 
An Rsym value of 3% is permissible in the low resolution shells and upto 20% is 
deemed acceptable in the high resolution shells (Diederichs and Karplus 1997). 
 
1.10  PHASING METHODS 
 For each of the thousands of intensities recorded, the phase must be calculated 
for every reflection. Following are the methods used to initially estimate phases. 
 
1.10.1 Multiple isomorphous replacement (MIR) 
 The addition of a heavy atom can cause a significant perturbation in the 
diffraction pattern which can be used to estimates phases (Patterson 1934). Usually 
for proteins, heavy atoms like lead, mercury or gold are used to produce such 
perturbations. This method is called isomorphous replacement or the heavy atom 
method. A native dataset and derivative datasets are collected. For a reflection, the 
native amplitude |FP| and the equivalent derivative amplitude |FPH| (contribution from 
protein and heavy atom) are compared to get the difference in amplitudes |FPH - FP| 
(Fig. 1.10) to get the amplitude contribution of only the heavy atom in the unit-cell. 
This is used to compute the diffraction pattern of just the heavy atom and to 
subsequently find the location (phases) of the heavy atomin the unit-cell. The native 
and derivative crystals are required to be isomorphic (Taylor 2003), meaning, the 




The structure factor of the heavy atom derivative is the sum of the 
contributions from the native crystal and the heavy atom.  
FPH=FH  + FP   Equation (6) 
 
Figure 1.10. Vector Representation of Structure Factors. 
Representation of FPH = FH  + FP  
 
The amplitudes and phases of the heavy atom derivative are known, so is |FPH| 
and |FP|. The phase is computed by means of Harker diagrams. To solve the above 
equation for FP, vector FH is drawn and a circle is drawn with radius |FPH| with the 
head of vector FH as the origin (Fig. 1.11). Another circle of radius |FP| is drawn with 
origin as the tail of vector FH. The point of intersection of the circles gives the phase 
of vector FP. Since there are two intersecting points, a data set collected with another 






Figure 1.11. Vector Solution in Isomorphous replacement. Vector 
representation of solution to equation FP  =  FPH - FH. The point of 
intersection of the circles on the right gives the phase of vector FP 
(Rhodes 2006).  
 
 
1.10.2  Anomalous scattering (MAD, SAD) 
It is another technique of obtaining phases using some atom’s ability to absorb 
X-rays of a specific wavelength (called the absorption edge of the atom). Due to this 
absorption, the Friedel pairs of reflections are not equal in intensity. This 
phenomenon is also known as anomalous dispersion. Two datasets are collected, one 
with anomalous dispersion and another away from the absorption edge. The 
difference in intensities between the two datasets is used to locate the ‘special’ atom. 
Subsequently, in a manner similar to isomorphous replacement, the phases of all 
reflections are obtained from a series of Harker diagrams. SAD phasing involves data 
collection at a single wavelength with anomalous scatterers within the macromolecule 
such as sulfur atom in cycteines and methionines used to derive the phases of the 
heavy atoms.  
 
1.10.3  Direct methods 
 The statistical relationships among structure factors are used to infer phases 




atoms increases, limiting this technique to solve structures with a few hundred atoms 
in the asymmetric unit. Another technique used by programs such as Shake-and-Bake 
is a random rearrangement of atoms that would produce the observed diffraction 
pattern. This method works only when the unit-cell is relatively small and the number 
of reflections are a few. 
 
1.10.4  Molecular replacement (MR) 
Since proteins with a similar function tend to have the same fold and 
conformation, the protein of the same family with a known structure can be used as a 
phasing model to initially estimate phases. This enables structure determination from 
a single native dataset. The structure factors derived from the crystal are combined 
with the phases from the model. The position and the orientation of the search model 
must be such that the Patterson peaks of the model and the target protein are similar. 
This is verified by doing a systematic translational and rotational search to find the 
correct position and orientation. A less intensive technique is to do a separate 
rotational and translational search (Rossmann and Blow 1962).  
 
1.11  ELECTRON DENSITY MAPS AND REFINEMENT 
 Once initial phases are estimated, an electron density map is constructed 
which is iteratively improved through model building and refinement. It involves 
adjusting the atomic coordinates so that the amplitudes calculated from the model 
match the experimental amplitudes. In the case of a small molecule, in which electron 
density is calculated near atomic resolution, atoms appear as clear peaks in an 
electron density map. A physical model is built into the electron density obtained 




of the models to fit within the electron density, which is constructed as a three-
dimensional mesh.  
The 2Fo-Fc difference map is used to get the initial three-dimensional map that 
accommodates the model. Map fitting or building a model into this density is 
nowadays handled by automated computer graphics programs. If the fitting is right, 
successive maps calculated lead to an improvement in the model. 
In an attempt to remove bias of the model, contour maps, such as the Fo - Fc 
map, are used so that the observed intensities can influence further corrections in the 
model.  This map is used to detect subtle errors in the built model. It removes the bias 
of the existing model by using the observed data to get positive and negative 
densities. A positive density in a region indicates that more electron density is 
actually present in the unit-cell than that which is represented in the model. Moving 
atoms in the model closer to the density will correct for this error. Similarly, a 
negative density is corrected for by moving atoms away form the region (McRee 
1999). It is used at the end of refinement when most of the major errors in the model 
have been removed.  
 A number of parameters are used to assess model quality such as the atomic 
bond length values, which must be close to canonical values. But, the principal 
criteria used to judge the correctness of the model is the difference between the 
observed and calculated structure factors. This correlation is expressed as the R 
factor. 
 
1.12  STRUCTURE VALIDATION  
 Comparison of the measured structure factor amplitudes Fobs and the 




model becomes closer to the actual structure, the observed and the calculated structure 
factor converge. A measure of this convergence is called the residual index or the R 
factor. A target for a well –refined structure is usually less than 0.3 (Morris, 









R    Equation (7) 
Another parameter, the Rfree is used to check how well the current model 
correlates to the set of intensities that were not included during data processing. A 
percentage of the intensities (usually 5% to 10%) is set apart during data processing 
and not used for refinements (Brunger 1992). This cross-validation technique gives a 
less biased and a better method of assessing model quality. Also, program suites are 
available such as PROCHECK (Laskowski, MacArthur et al. 1993) and Molprobity 
(Davis, Leaver-Fay et al. 2007) to check the geometrical integrity and other 
parameters of the final model, before it is deposited. In a well-refined structure, the 
root mean square deviation (RMSD) of bond length should be lesser than 0.02 Å and 















2.1 SECOND MESSENGERS IN BACTERIA 
Discovered initially in 1987 by Moshe Benziman and colleagues during their 
work on cellulose synthase, cyclic-di-GMP is a vital second messenger present 
predominantly in bacteria. Cyclic-di-GMP was originally identified as an allosteric 
activator of the enzyme cellulose synthase (Ross, Weinhouse et al. 1987). This 
finding lead to the discovery of the enzymes that regulate the levels of this molecule 
within bacterium –di-guanylate cyclase (DGC) and phosphodiesterase A (PDEA) 
(Tal, Wong et al. 1998). This signaling molecule has been attributed to numerous 
functions such as biofilm formation, transition to a motile form, virulence, cell 
differentiation and host cell cytotoxicity (Furukawa, Kuchma et al. 2006). 
 
2.2 GENOMIC CONTEXT OF CYCLIC-DI-GMP 
The presence of cyclic-di-GMP pathways has been experimentally confirmed 
for the main phylogenetic classes of bacteria that includes Probacteria, 
Cyanobacteria, Thermotogae, Actinobacteria etc. (Sudarsan, Lee et al. 2008, 
Bordeleau, Fortier et al. 2011). The number of bacterial species containing the 
GGDEF domain far exceeds the number of species that have the adenylate and 
guanylate cyclase domain (Sinha and Sprang 2006), establishing that cyclic-di-GMP 
is a more pervasive signaling molecule compared to cAMP in bacteria. The GGDEF 
and EAL domains have been found to exist in association with other sensory domains 
that respond to upstream signaling molecules and subsequently regulate these 
domains. In G. xylinus, an oxygen sensing PAS domain is present in DGCs and PDE 




associated with the GGDEF domain (Galperin, Nikolskaya et al. 2001) as a part of the 
bacterial two component signaling mechanism.  
 For the enzymes linked to PAS and GAF domains, modulation occurs through 
the binding of ligands such as heme, flavin nucleotides and other chromophores. 
These domains help the protein to sense and respond to NO, CO, O2, the redox state 
of the electron transport chain components and various other external stimuli. These 
proteins respond to such signals by altering the synthesis or degradation of cyclic-di-
GMP.  
 In addition, many GGDEF and EAL domains are coupled to REC domains, 
which make them a part of two-component signal transduction systems (Fig. 2.1) that 
consist of a sensory histidine kinase (HK) and its cognate response regulator (RR) 
(Stock, Robinson et al. 2000), allowing bacteria to respond to nutrients, osmolarity, 
quorum signals and antibiotics (Wolanin, Thomason et al. 2002).  
 
Figure 2.1. Bacterial Two-component signaling systems Taken from 
http://syntheticmicrobe.bio.lmu.de/research/stimulus_percept/index.ht
ml The extracellular signals are conveyed via transmembrane domains 





2.3 CYCLIC-DI-GMP CONTROL MODULE 
A second messenger control module typically consists of four components: 
two enzymes involved in the synthesis and degradation of the molecule in response to 
signals, an effector that is allosterically regulated by a messenger and a target 
molecule that comes in contact with an effector to produce a molecular output, e-g. 
cAMP control module (Botsford and Harman 1992). For cyclic di-GMP, this module 
involves DGCs and PDEs that affect an output through a common pool of the 
messenger. Different types of targets and effectors control the activity and expression 
of different DGCs and PDEs in different modules to control a range of cellular 
functions (Hengge 2009).  
 
2.3.1 Cyclic-di-GMP module inputs  
 Most GGDEF, EAL and HD-GYP domains consist of N-terminal regulatory 
domains, which are sensory input domains that respond to environmental and cellular 
signals. This creates a complex cyclic-di-GMP signaling network (Galperin, 
Nikolskaya et al. 2001). Many of the proteins in this pathway contain transmembrane 
helices that can respond to light, oxygen, redox conditions, antibiotics and other 
intracellular signaling molecules. Moreover, the synthesis or degradation of cyclic-di-
GMP can be the outcome of two–component signaling pathways when the 






Figure 2.2. Cyclic-di-GMP signaling mechanisms. Possible 
mechanisms by which the signaling pathway may be regulated 
(Romling, Galperin et al. 2013) A) When phenotype output requires 
more than one target, each of the targets is controlled by distinct 
signaling pathways involving cyclic-di-GMP metabolizing enzymes 
and effector molecule B) A single target controlling phenotype where 
multiple DGCs regulate an effector C) Different effectors regulate the 
phenotype where each effector is regulated by specific DGCs 
 
 
A single bacterial species encodes for a number of GGDEF and EAL domain 
containing proteins that raises the question of signal specificity. Fig. 2.2 shows the 
possible mechanism by which a pathway can be organized. Nevertheless, the presence 
of many domains with the same function can eliminate signal specificity and give rise 
to noise that can disrupt the signaling system. A solution to this could be the 
sequestration of these domains so that not all of the domains are present at the same 
place and at the same time (Hengge 2009). This way the signaling modules operate in 
physically separate entities. For example, in Yersinia pestis, the GGDEF domain 
containing protein HmsT is degraded by proteases under low temperature conditions 
(Kirillina, Fetherston et al. 2004). Also, the DGC, PDE and glycosyltransferase in 
Yersinia pestis involved in biofilm associated traits and exopolysaccharide secretion 
interact specifically with each other and are all attached to the cell membrane 





2.3.2 Cyclic-di-GMP module targets 
 A signal is relayed by cyclic-di-GMP that binds to effector molecules and 
alters their structure and function. Currently there are many effector molecules 
identified which include both proteins, such as FleQ (Hickman and Harwood 2008), 
YcgR (Ryjenkov, Simm et al. 2006), DgrA (Christen, Christen et al. 2007) from the 
PilZ family and RNA effectors that include Vc1, Vc2 and Cd1 (Sudarsan, Lee et al. 
2008). Some of the key processes regulated by this molecule include expression of 
flagellar genes, biofilm formation, expression and adhesion of fimbriae and cellulose 
synthesis. 
 
2.4 PHYSIOLOGY OF CYCLIC-DI-GMP SIGNALING  
Fig. 2.3 shows the functions regulated by cyclic-di-GMP signaling. Cyclic-di-
GMP is found to regulate critical functions that include biofilm formation and 
virulence.  
 






2.4.1 Switch between motile and sessile state 
Majority of bacteria remain attached to surfaces and the transition to this 
sessile state involves many changes that include multicellular growth as a colony or 
biofilm formation.  In flagellated bacteria, high levels of intracellular cyclic-di-GMP 
induced by deletion of the major phosphodiesterase in E. coli created a bias for 
counterclockwise motion of flagella (Girgis, Liu et al. 2007). A counterclockwise 
motion is important in propelling the cell forward and creating a change in direction. 
Hence, the bacteria that are unable to change direction did not spread in semisolid 
agar and trapped in the medium (Wolfe and Berg 1989). When the cyclic-di-GMP 
receptor YcgR that is motility specific was inactivated, it restored the motility of the 
bacteria in semisolid agar (Ryjenkov, Simm et al. 2006).  
 Transcriptional regulation of certain flagellar genes is also undertaken through 
cyclic-di-GMP in some bacteria. It is involved in the inverse regulation of certain 
flagellar genes and genes that synthesise protein adhesins, polysaccharides adhesive 
pili and other genes characterizing a surface-attached biofilm lifestyle (Jyot, Dasgupta 
et al. 2002, Lee, Weng et al. 2003). 
 
2.4.2 Biofilm formation 
Several studies demonstrate that cyclic-di-GMP promotes biofilm formation. 
Increased levels of this molecule induce biofilm formation and reduced levels 
increase motility and cytotoxicity (Jenal and Malone 2006), suggesting that the 
molecule and the enzymes regulating its levels are highly regulated. An increased 
level of cyclic-di-GMP has been shown to express more adhesive matrix components 




microbes. There is increasing evidence associating chronic bacterial infections and 
biofilm formation in the host (Hall-Stoodley, Costerton et al. 2004).  
The extracellular components that lead to biofilm formation such as exo 
polysaccharides, adhesive pili, adhesins and extracellular DNA have been shown to 
be regulated by cyclic-di-GMP (Romling 2012). Cellulose is a common component of 
bacterial biofilms (Monteiro, Saxena et al. 2009, Saldana, Xicohtencatl-Cortes et al. 
2009). Initially discovered as a regulator of cellulose biosynthesis in G. xylinus, this 
molecule was found to bind to the PilZ domain of cellulose synthases. Since bacteria, 
such as G. xylinus, E. coli and S. enterica, express cellulose synthases constitutively, 
cyclic-di-GMP exerts a post-translational control of cellulose synthesis. 
Poly-β-1,6-N-acetyl glucosamine (PAG) is an exopolysaccharide produced by 
bacteria as a biofilm matrix component (Itoh, Wang et al. 2005). In Y. pestis, the 
proteins that synthesize PAG are co-localized with the enzymes metabolizing cyclic-
di-GMP (Kirillina, Fetherston et al. 2004). In E. coli, two DGCs were found to 
regulate PAG biosynthesis, one of them affecting the transcription of the PAG 
biosynthesis operon and the other stabilizing the structural proteins responsible for 
PAG synthesis (Boehm, Steiner et al. 2009, Tagliabue, Antoniani et al. 2010).  
Bacterial multirepeat adhesins contribute to biofilm formation through 
components stabilizing the extracellular matrix. LapA is a protein in Pseudomonas 
putida and fluorescens that facilitates cell-to-cell interconnection in biofilm thereby 
preventing its dispersal (Hinsa, Espinosa-Urgel et al. 2003). LapA is attached to cell 
surface, promoting adhesion, or can undergo N terminal proteolysis to be released 
into the medium. The mechanisms regulating LapA proteolysis are dependent on a 
cyclic-di-GMP signaling network that responds to low levels of inorganic phosphate 




All classes of fimbriae (pili), the non-flagellar filamentous appendages have 
been associated with biofilm formation and are indicative of regulation by cyclic-di-
GMP signaling. A negative regulation of fimbrial expression has been observed for a 
number of bacteria. For example, in Klebsiella pneumoniae, a pathogen involved in 
respiratory tract infections, cyclic-di-GMP was found to activate the transcription of a 
set of fimbrial genes. Cyclic-di-GMP was found to activate a transcription factor 
containing a PilZ domain and a DNA binding domain (Wilksch, Yang et al. 2011). 
Also, a DGC was identified to have stimulated the expression of type 3 fimbriae and a 
PDE that can down regulate fimbriae expression.  Cyclic-di-GMP has also been 
linked to the regulation of type IV pili, the most ubiquitous kind. These pili contribute 
to twitching motility due to their ability to polymerize and retract. This property is 
required for the formation and maturation of biofilms into a three-dimensional 
architecture. The response regulator FimX, a multidomain protein that has the 
GGDEF and PDE domains, controls biogenesis of this type of pili in Pseudomonas 
aeruginosa (Huang, Whitchurch et al. 2003).  
The role of this molecule in biofilm formation has been confirmed as 
screening for virulence factors points to the GGDEF and EAL domain proteins in 
organisms such as V. cholerae (Tischler and Camilli 2005), X. campestris and P. 
aeruginosa (Kuchma, Connolly et al. 2005). 
 
2.4.3 Regulation of cell cycle and differentiation by cyclic-di-GMP 
Caulobacter crescentus undergoes differentiation from a motile state to form a 
stalked cell that undergoes cell division to produce a motile cell. This process is 
tightly coupled to the initiation of cell cycle. Increased levels of cyclic-di-GMP result 




DGCs – PleD and DgcB have been shown to drive stalk initiation and elongation 
(Abel, Chien et al. 2011).   
A link to cyclic di-GMP signaling was established in the multi-cellular 
cyanobacterium. Upon inactivation of one of the DGCs, the number of vegetative 
cells between heterocysts was found to increase from 25 to 200 (Neunuebel and 
Golden 2008). Also, in the life cycle of Sterptomyces species, overexpression of a 
DGC resulted in the impaired formation of mycelium that is required for spore 
formation while deletion of another DGC impaired hypha formation from the spore 
(Tran, Den Hengst et al. 2011).   
 
2.4.4 Virulence 
Cyclic-di-GMP has been known to influence virulence in numerous plant and 
animal pathogens. In a study of mouse models of cholera, low levels of cyclic-di-
GMP favored expression of the cholera toxin whereas, high levels of this molecule 
attenuated virulence (Tischler and Camilli 2005). Contrarily, in the case of mouse 
model infection of Pseudomonas aeruginosa, the virulence was reduced in deletion 
mutants for phosphodiesterases (Kulasakara, Lee et al. 2006) as well as for a mutant 
of a DGC. Cyclic-di-GMP metabolizing enzymes that are opposite in function seem 
to be required for infection. A similar phenomenon was observed in the case of S. 
enterica infection. This suggests that there is a complex network of interaction 
between the bacteria and host with the pathogen adapting to changes within the host. 
The increased virulence of pathogen mutants that have high levels of cyclic-di-GMP 
indicate that biofilm related functions are essential in establishing an acute phase of 




Additionally, a number of phenotypes are associated with cyclic-di-GMP 
signaling such as host cell adherence, invasion, secretion of virulence factors and 
modulation of immune response. All types of secretion systems are shown to be 
regulated by cyclic-di-GMP mediated signaling (Romling, Galperin et al. 2013). 
 
2.5 INTERPLAY BETWEEN QUORUM SENSING AND CYCLIC-DI-GMP 
SIGNALING  
The two well-known strategies that bacteria use to respond to population 
changes and environmental stimuli are quorum sensing and cyclic-di-GMP signaling 
(Srivastava and Waters 2012). The two mechanisms are to be interwoven either 
directly or indirectly in which a direct control involves an autoinducer regulating the 
levels of an enzyme involved in cyclic-di-GMP synthesis/degradation (e.g. X. 
campestris) and an indirect control includes regulation of cyclic-di-GMP at various 
levels downstream in the signaling pathway initiated by an autoinducer  (eg. V. 
cholerae).  
 
















Bis-(3´-5´)-cyclic dimeric GMP has a two-fold symmetry with two GMP 
moieties linked by O3´–P phosphodiester bonds (Fig. 2.4) creating a 12 membered 
macrocycle. Conformation A (Fig. 2.5) is a rigid scaffold with torsion only around the 
glycosidic bond and variable orientation of the guanyl base. These molecules can also 
associate to form a dimer with a two-fold symmetry as observed in crystal structures 
(PDB code – 3IGN, 2V0N). This conformation, shown in B, has intercalated bases 
and hydrogen bonds between the base and phosphate group and this form has been 
shown to bind to the allosteric inhibitory site.  
 
 
Figure 2.5. Forms of cyclic-di-GMP. A) a monomer of cyclic-di-
GMP having two GMP moieties linked by a phosphodiester bond. B) 
dimeric form of cyclic-diGMP with a two-fold symmetry with stacked 
bases (Romling, Galperin et al. 2013). 
       
The structures of cyclic-di-GMP on the left panel shows the molecule in a monomeric 
form, typically seen bound to the EAL domain. The dimeric form (right panel) is 
usually seen bound to the allosteric site in the GGDEF domain. Higher oligomeric 
forms are known to exist in solution but their physiological relevance is still unknown 
(Gentner, Allan et al. 2012). 
 
2.7 SYNTHESIS AND DEGRADATION OF CYCLIC-DI-GMP 
 Cyclic-di-GMP is synthesized from two molecules of GTP. Two molecules of 






Figure 2.6. Hypothesized mechanism of cyclic-di-GMP formation. 
Adapted from - http://en.wikipedia.org/wiki/Diguanylate_cyclase. The 
proposed mechanism of cyclic-di-GMP formation involves 
deprotonation by a glutamate residue at the active site followed by 
nucleophilic attack on the α phosphate (Chan, Paul et al. 2004). 
 
 
Each GGDEF domain contributes a GTP molecule to form an intermolecular 
phosphoester bond with the neighboring GTP molecule. Two monomers come 
together to create an active site at the dimer interface (Paul, Abel et al. 2007). In a 
study on GGDEF domains from different branches of the bacterial phylogeny, the 
individual domains were found to possess activity. In those enzymes for which full 
length protein was expressed, the domain was active only upon activation 
(phosphorylation) of the associated REC domain, demonstrating that this domain is 
strongly influenced by neighboring domains and interacting proteins. This suggests 
that the regulating domains keep the catalytic domains physically separated from each 
other. Also, it was shown that the GGDEF domain is only associated with cyclic-di-





Figure 2.7. Regulation of cyclic-di-GMP. Two antagonistic activities 
of biofilm formation and motility and associated virulence controlled 
by cyclic-di-GMP which is in turn regulated by the opposing activities 
of GGDEF and EAL domain containing proteins. The dashed lines 
indicate allosteric control over the domains (Jenal and Malone 2006). 
 
2.8 EAL DOMAIN 
Cyclic-di-GMP is generated from two GTP molecules by diguanylate cyclases 
whereas proteins containing the EAL domain convert cyclic-di-GMP into the linear 
form pGpG. The name of the domain originates from its conserved amino acid 
signature – EAL (Glu--Ala-Leu). This reaction is involves the hydrolysis of an ester 
bond to give a linear dinucleotide, 5´-phosphoguanylyl-(3´-5´)-guanosine (pGpG). 
The catalysis is dependent on Mn2+ or Mg2+ ions and is inhibited by Ca2+ or Zn2+ ions 
(Christen, Christen et al. 2005, Schmidt, Ryjenkov et al. 2005). The EAL domains 
have a TIM barrel (βα)8 fold (a central β-barrel flanked by α-helices). In many 
proteins, the EAL domain is present C terminal to the GGDEF domain and often 
associated with accessory domains such as PAS, GAF, BLUF and REC.  These linked 
domains appear to have regulatory functions. For example, in the composite protein 
PdeA from Caulobacter crescentus, there is evidence of crosstalk between the 




but is able to bind to GTP and allosterically activate the neighbouring EAL domain 
(Christen, Christen et al. 2005). 
 
Figure 2.8. Structure of BlrP1. (PDB-3GFY) It has a blue light 
sensing domain (BLUF) and phosphodiesterase (EAL) domain (green). 
 
2.9 HD-GYP DOMAIN 
The HD-GYP domain also hydrolyzes cyclic-di-GMP. It is widespread in 
bacterial genomes even though not ubiquitous as the EAL domain. It belongs to the 
HD domain family that catalyzes phosphomonoesterase and phosphodiesterase 
reactions that have a conserved HHExxDGxxGYP motif (Dow, Fouhy et al. 2006) 
with a catalytic metal center that is mononuclear or binuclear respectively (Aravind 
and Koonin 1998). These domains have been shown to hydrolyze cyclic-di-GMP in a 
two-step reaction mechanism via pGpG to produce cGMP (Stelitano, Giardina et al. 
2013). Recent crystal structures of a thermophilic HD-GYP, complexed with product 
and substrate, reveal the presence of a tri nuclear metal catalytic center. Also, the 
mode of binding of the substrate is distinct from that of the well-characterized EAL 
domains (Lovering, Capeness et al. 2011, Bellini, Caly et al. 2013, Wigren, Liang et 




                              
Figure 2.9. HD-GYP Domain. Structure of HD-GYP domain linked 
to a N terminal GAF domain from Persephonella marina 
 
2.10 STRUCTURE AND REGULATION OF DI-GUANYLATE CYCLASES  
The synthesis of cyclic-di-GMP is due to two GGDEF domains, each of which 
binds to a GTP molecule. DGCs usually have N terminal accessory domains that 
regulate this domain. 
The GGDEF domain has a central β-sheet surrounded by α-helices with a 
topology similar to class 3 adenylate cyclases and the palm domain of type 1 DNA 
polymerases due to the similarity of the reactions catalyzed. An extensively studied 
DGC is the PleD from Caulobacter crescentus shown to be essential for swarmer-cell 
to stalked-cell diffrentiation and stalk biogenesis (Aldridge, Paul et al. 2003). This 
protein has two CheY-like phosphoreceiver domains and a C terminal GGDEF 
domain. Two crystal forms of this enzyme have been studied, one with cyclic-di-
GMP bound to the A site and a second form with GTPαS bound to the active site. 







Figure 2.10. Crystal Structures of PleD. The view is perpendicular to 
the two fold axis, the active site is shown in blue (A) the structure of 
non-activated PleD, The cyclic-di-GMP binds to I site residues as well 
as secondary sites on the adaptor domain. B) PleD activated by BeF3 – 
the cyclic-di-GMP binding at the I site crosslinks the two GGDEF 
domains, having primary I site from one chain and secondary binding 
sites on the other chain (PDB – 1W25, 2V0N) (Wassmann, Chan et al. 
2007).  
 
The PleD has conserved residues at the N terminal domain that are responsible 
for phosphate binding and at the active site involved in nucleotide binding and 
coordination to metal ions. The C terminal domain is a central β-sheet with 5 strands 
surrounded by α-helices. The GGDEF motif is located on a tight turn between two β-
strands (Chan, Paul et al. 2004).  
 
2.10.1 I site 
The crystal structure of PleD has an allosteric binding site at the interface of 
the GGDEF and REC2 domains. Sequence alignments of more than thousand 
GGDEF domains have revealed that residues R359 and D362 of the I site are highly 
conserved in more than 57% of the proteins (Christen, Christen et al. 2006). Cyclic-




with specific residues at the REC2 domain and the GGDEF domain. The ligand dimer 
has two mutually intercalated purine bases with each guanyl moiety forming a 
hydrogen bond with the phosphate group. A tight binding of the ligand to the I site 
was observed as it co-purifies with the protein. Fig. 2.11 illustrates the arginine- 
guanine interactions, involving the interaction of O6 and N7 of guanine with R390 
and R359 of the GGDEF domain and R178 of the REC2 domain (Chan, Paul et al. 
2004). 
When mutated, residues R359 and D362 (part of the conserved RxxD motif of 
the I site) completely failed to bind to cyclic-di-GMP. Also, cyclic-di-GMP binding 
was normal in the DGC protein that lacked the REC1 domain or when a tryptophan, a 
bulky residue, was introduced at the GGDEF-REC2 interface, implying that only the 
residues in the GGDEF domain are structurally important for the binding of ligand to 
the I site. Moreover, R359, D362 and R390 form an allosteric binding pocket for the 
ligand.  
 
                           
Figure 2.11. Arginine – Guanosine interaction. The GGDEF 
residues are shown in cyan and that from the REC2 domain are in 






A similar dimeric form of cyclic-di-GMP was bound to the I site in the crystal 
structure of WspR (De, Pirruccello et al. 2008) and a recent crystal structure of a 
stand alone GGDEF domain from Marinobacter aquaeolei (Vorobiev, Neely et al. 
2012).  
Currently there are two theories explaining the inhibition of DGCs by cyclic-
di-GMP: inactivation by domain immobilization and allosteric mechanism. According 
to the first theory, the product cyclic-di-GMP immobilizes the catalytic domain, 
trapping the catalytic site of each chain away from each other, as shown in Fig. 2.12. 
This conformation is mediated by the cyclic-di-GMP dimer, which bridges the two 
catalytic domains and also crosslinks the catalytic and the REC domain as in the case 
of PleD. Nevertheless, since a variety of sensing domains are associated with DGCs, 
it is speculated that an I site formed by the interface of GGDEF and regulatory 
domain may not be applicable in all DGC containing proteins (Christen, Christen et 
al. 2006). 
 
Figure 2.12. Crosslinked DGC domains in PleD. DGC dimer along 
symmetry axis with the ligands bound to Ip (primary I site) and Is site 





According to the allosteric mechanism, the binding of cyclic-di-GMP causes 
changes in the active site of the molecule. Though the active and the inhibitory sites 
are near in the primary sequence, they are located on opposite ends of the molecule, 
on either side of a β-strand. In a study performed on the PleD structure, simulation 
study of the liganded and unliganded protein indicated a decrease in the flexibility of 
the Cα atoms, in both the A site and I sites, upon ligand binding. The energy 
minimized structures of the GGDEF domain from PleD with and without the bound 
ligand at the I site are shown in Fig. 2.13. It was shown that that the β-strand between 
the A site and I site undergoes a balance-like movement that considerably repositions 
the residues at the active site. The main chain carbon atoms and side chains were 
displaced by 1-4 Å in opposite directions, implying a dynamic coupling between the 
two sites. An intrinsic allosteric mechanism was also proposed as the inhibitory 
mechanism of all DGCs with the signature RxxD motif (Christen, Christen et al. 
2006). 
                       
Figure 2.13. Energy minimized structures of PleD. DGC domain 




upon ligand binding are shown in green (I site) and yellow (A site) 
(Christen, Christen et al. 2006). 
 
The structure of a DGC without an I site has been solved with the bound 
product at the A site in a partially intercalated form (Yang, Chin et al. 2011).  The 
bound product mediates dimer formation in which the peripheral bases are bound to 
the active site and the central bases are stacked.  The binding of product is indicative 
of a new mechanism of product mediated inhibition in GGDEF domains that lack the 
I site consensus sequence.  Studies of another DGC (YfiN) from Pseudomonas 
aeruginosa which lacks the I site indicate that the N terminal transmembrane region 
activates or inactivates the intracellular DGC domain by altering dimer orientation 
(Giardina, Paiardini et al. 2013). 
 
2.10.2 A site 
 The structure of PleD with the GTPαS analog bound to the active site has been 
solved (Wassmann, Chan et al. 2007).  The guanine base is present in a pocket formed 
by helices α1 and α2 as shown in Fig. 2.14. All the atoms of the base, except O6, 





Figure 2.14. GTPαS binding pocket in PleD The omit map of the 
ligand in contoured at 3σ, the residues binding to GTP analog are 
shown with side chains in cyan (Wassmann, Chan et al. 2007). 
 
Glu371 in the GGDEF sequence is a requisite for catalysis. It is speculated to 
coordinate to a metal ion transiently or serve as a proton acceptor for the incoming 3′ 
phosphate from the other subunit. The Asp327 and Glu370 coordinate to a second 
magnesium atom.  Lys332 is another residue that is believed to stabilize the transition 
state.  
 The formation of an active state requires an antiparallel orientation of the two 
domains so that the 3′ hydroxyl groups are brought close to the α-phosphate of the 
cyclic-di-GMP from the other domain for nucleophilic attack. Modelling studies 
propose that formation of such a dimer, mediated mainly by intermolecular salt 
bridges, is possible without any clashes (Wassmann, Chan et al. 2007). 
 
2.10.3 Oligomerization, activity and inhibition of PleD 
 Extensive studies on PleD indicate that the active form of the enzyme is 
dimeric (Paul, Abel et al. 2007). The relative activity of the enzyme was found to 
increase with the concentration of the enzyme both in the case of the nonactivated and 




oligomerization. Crosslinked enzymes that were activated with BeF3 showed a 6-fold 
increase in activity, compared to the non-crosslinked samples. The formation of 
dimers was confirmed by size exclusion chromatography. Moreover, activation of the 
protein prior to crosslinking resulted in an increase in the fraction of dimers.  
 Furthermore, to confirm if the activity of the enzyme influences dimerization, 
an active site mutant, E370Q, was checked. The mutated glutamate residue is 
hypothesized to coordinate to a magnesium ion and deprotonate the hydroxyl group of 
GTP. There was no detectable enzyme activity even at concentrations of 50 µM and 
prolonged incubation times, despite being dimeric like the activated wild type 
enzyme. It was concluded that dimerization is a requisite for catalysis and that 
oligomerization is not affected by the activity of the enzyme.  
To examine the influence of feedback inhibition in a catalytically active 
dimer, both the activated and nonactivated forms of the protein was checked by 
isothermal calorimetry for cyclic-di-GMP binding. Both cases had a similar binding 
stoichiometry of 2:1, indicating that dimerization and product inhibition are two 
different areas of DGC control. 
 
2.10.4  Oligomerization and regulation of WspR 
WspR is an ortholog of PleD that has an N terminal CheY-homology 
phosphoreceiver domain and a C terminal GGDEF domain with the RxxD motif (De, 
Pirruccello et al. 2008). The protein known to control biofilm formation (Hickman, 
Tifrea et al. 2005) is regulated by phosphorylation of its N terminal domain. 
Structural characterization of this protein indicates that its inhibition is dependent on 
oligomerization rather than phosphorylation. The crystal lattice packing of this 





Figure 2.15. Crystal Structure of WspR A) Crytal Structure of WspR 
in an inhibited conformation with cyclic-di-GMP bound to the I site. 
The active site residues are shown in yellow B) Inhibited tetrameric 
form of WspR mediated by stalk domain (De, Pirruccello et al. 2008)  
 
2.10.4.1 Oligomerization for feedback inhibition 
Cyclic-di-GMP was found to co-purify with the enzyme and could be removed 
through phosphodiesterase treatment. However, enzymes with mutations at the active 
site (GGAAF) purified without the nucleotides indicating that enzyme activity is 
required for product binding at the I site. However, after purification, the enzyme 
could bind to the product upon incubation with free cyclic-di-GMP. Two other I site 
mutants, R242A and R198A that could be purified free of nucleotide and exhibited 
high catalytic activity, were also studied. 
 
2.10.4.2 Distinct dimeric states 
The nucleotide bound and nucleotide free WspR could be distinguished from 
their different elution volumes during gel filtration. This was indicative of different 
conformations of the protein. Static Light Scattering (SLS) experiments showed that 




both protein forms were dimeric but had different hydrodynamic radii. The nucleotide 
bound form is in an elongated conformation whereas the PDE treated form of the wild 
type is more globular. In the absence of cyclic-di-GMP, prolonged incubation resulted 
in the formation of a small fraction of the tetrameric state. Also, the other active site 
mutant (GGAAF) and I site mutant R242A and R198A mutant that were purified free 
of nucleotides formed distinct dimeric (compact dimer) and tetrameric species, 
indicating that tetramerization is driven by stalk motif contacts rather than cyclic-di-
GMP.  
The activities of the different oligomeric species did not have any effect upon 
phosphorylation, indicating the dimerization is constitutive. The active site mutant 
GGAAF was inactive. Of the different nucleotide free dimeric forms, wt, R198A and 
R242A, the elongated and compact forms were distinctly inactive and active. The 
nucleotide bound wild type protein was an elongated dimer and exhibited slow 
kinetics. The other compact dimeric forms (nucleotide-free WspR wt, R198A WspR 
and R242AWspR) were highly active (De, Pirruccello et al. 2008).  
The residues on the stalk, thought to be involved in dimer formation, when 
mutated, gave rise to two different forms of dimer and both forms were copurified 
with cyclic-di-GMP. L170D eluted as a compact dimer and had good activity whereas 
L167D eluted as a weakly associated dimer and was inactive. This established that the 
dimerization was mediated by the coiled-coil motifs. 
 
2.10.4.3 Model for activation and inhibition 
The wild type enzyme that purified with cyclic-di-GMP existed as an 
elongated and inhibited dimer that switched to a compact dimer upon treatment with 




were incubated in cyclic-di-GMP to check for reversal to inactive form. The protein, 
when concentrated relatively, changed to the elongated dimeric conformation. 
Surprisingly, below this limit, the protein remained in a compact dimeric form. Based 
on these observations, a model for the transition of the compact active dimer into an 
elongated inactive dimer, through the formation of an inactive tetrameric species, was 
proposed, Fig. 2.16 (De, Pirruccello et al. 2008). 
In vivo experiments have shown that WspR when activated forms subcellular 
clusters supporting a model in which a high intracellular concentration of WspR is 
required for diguanylate cyclase activity (Huangyutitham, Guvener et al. 2013).  
 
Figure 2.16. Model for the mechanism of activation and inhibition 
of WspR through oligomerization The tetramer acts as a scaffold that 
assembles from the compact active dimer and dissociates into the 
inactive dimeric form. Upon treatment with phosphodiesterases, the 
elongated dimer reassembles into an active compact dimer. 
 
 
2.10.4.4 WspR from Pseudomonas syringae 
Also, studies on another WspR from Pseudomonas syringae confirm the 
tertrameric model, proposed for the formation of inhibited dimer (De, Navarro et al. 
2009). The crystal structure shows  this tetrameric conformation is mediated by stalk 




inactive, confirming inactivation by domain immobilization. Besides, in the structure 
of a GGDEF protein attached to a N terminal leucine zipper GCN4 (De, Navarro et al. 
2009), cyclic-di-GMP bridges the two GGDEF domains, with the active sites facing 
away from each other, similar to the crystal structure of PleD.  
 
2.11 SYNTHESIS OF CYCLIC-DI-GMP 
Analysis of macromolecules involved in cyclic-di-GMP signaling pathways 
requires the use of a large amount of this compound for biochemical assays. The 
presence of cyclic-di-GMP in very low quantities in bacterial cells eliminates 
isolation from native sources. Hence this molecule is either chemically synthesized or 
made by enzymatic means. The chemical methods of synthesis involve multiple steps 
that are time consuming and expensive (Ross, Mayer et al. 1990, Yan and Aguilar 
2007). Enzymatically, this reaction proceeds in a single step involving a nucleophilic 
attack. 
The currently used mesophilic DGC enzymes, such as PleD and WspR from 
Pseudomonas aeruginosa, yield only limited amounts of cyclic-di-GMP, due to low 
thermostability and allosteric product inhibition (Rao, Pasunooti et al. 2009). 
Although I site mutant of WspR has been shown to be highly active (De, Pirruccello 
et al. 2008), the use of a thermostable enzyme is advantageous in that the activity can 
be retained for prolonged duration of time at room temperature.  
 
2.12 ENZYMATIC SYNTHESIS OF CYCLIC-DI-GMP USING A 
THERMOSTABLE ENZYME 
The Liang lab reports a stand-alone thermophilic (residues 82 – 248) (tDGC) 




mesophilic proteins (Rao, Pasunooti et al. 2009). Furthermore, it was shown that a 
mutation at the allosteric inhibition site could improve the product yield many folds 
compared to the wild type enzyme. The C terminus (residues 82-241) of the 248 
residue TM1788 gene was cloned to express the GGDEF domain of the wild type 
protein. The study involved another construct with a mutation (R158A) at the highly 
conserved RxxD motif responsible for binding the product and mediating inhibition. 
The alignment of this thermophilic domain with other mesophiles is shown in Fig. 
4.31. 
 
Figure 2.17. Oligomerization of tDGC and R158 tDGC tDGC elutes as 
a dimer compared to the mutant which elutes as a monomer (Rao, 
Pasunooti et al. 2009) 
 
The oligomerization of the wild type and R158A mutant tDGC was strikingly 
different as shown in Fig. 2.17, with the wild type eluting as a dimer and the mutant 
as a monomer on a size exclusion column. This observation suggested that the 






2.12.1 Enzyme assays 
Enzymatic assays showed that the stand-alone domain is enzymatically active 
when incubated with GTP and Mg2+ ion. Cyclic-di-GMP was synthesized by 
incubating the mutant enzyme (5 to 10 µl) with GTP at 45 °C in a 30 ml reaction mix 
containing 50 mM Tris (pH 7.5), 250 mM Nacl, 20 mM MgCl2, 1 mM DTT, 1 mM 
GTP. Within 40 minutes, more than 95% of GTP was converted to cyclic-di-GMP as 
determined by HPLC analysis. Multiple batches (8-15) of GTP could be added over a 
time period of 10 hours following which, the protein was precipitated by heating and 
cyclic-di-GMP was purified from the supernatant by HPLC.  
The wild type tDGC showed remarkable thermostability and was active after 
several days of incubation at 30 °C. However, the wild type tDGC had a very low 
yield even after prolonged incubation time and a high substrate concentration. From 
site directed mutagenesis studies, the R158A mutant was found to have the best 
activity without any product inhibition. This mutation was found to completely 
abolish the binding of cyclic-di-GMP at the I site as shown in Fig. 2.18. Also, the 
mutant was able to convert 100% of GTP into product, suggesting no product 
inhibition. 
 
Figure 2.18. Absorption Spectra of tDGC and R158A tDGC The 
absence of an absorption peak at 256nm suggests that cyclic-di-GMP is no 





The yield for the mutant was much higher than the wild type tDGC as shown 
in Fig. 2.19. However, the activity of the mutant was found to be stable beyond a 
substrate concentration of 0.8 mM suggesting saturation. The wild type tDGC was 
inhibited even at a much lower substrate concentration of 100 µM. Steady state 
kinetic measurements, (Fig. 2.19) indicate that the mutant enzyme exhibits a kcat of 
2.6/min at 55 °C. 
 
Figure 2.19. Enzyme Assay Comparison of cyclic-diGMP 
synthesis at different substrate concentrations R158A tDGC at 




To optimize the reactions conditions for the mutant, systematic screening of 
pH, salt and temperature was performed (Fig. 2.20 and 2.21). Thermostability 
analysis showed that at higher temperatures, the enzymatic activity decreases with 
time. It was also shown that catalysis is efficient at pH 7.5 at a salt concentration of 





Figure 2.20. Optimum pH and salt concentration  
Salt and pH dependence of enzymatic activity of R158A 
tDGC (Rao, Pasunooti et al. 2009) 
 
 
Figure 2.21. Thermostability Analysis of R158A tDGC 
Production yield normalized to the highest yield at zero time 
point at various temperatures (Rao, Pasunooti et al. 2009) 
 
 
The R158A mutant enabled synthesis of more than 200 mg of cyclic-di-GMP 
with just 10 mg of the mutant enzyme by adding multiple batches of the substrate 
over a few hours. With the sequence of the construct optimized for bacterial 




Comparatively, with WspR, only 10-20 mg cyclic-di-GMP could be obtained with the 
use of 50 mg of the enzyme. 
 
2.13 SIGNIFICANCE AND OBJECTIVES OF THIS WORK 
A high level of cyclic-di-GMP within the cell is associated with biofilm 
formation and is required to establish an acute phase of infection for most pathogens. 
The formation of biofilms confers resistance to antibiotics and immune responses of 
host. As reduction in cyclic-di-GMP levels has been shown to inhibit biofilm 
formation, the analogues and derivatives of this compound are of interest to develop 
inhibitors for diguanylate cyclases. Also, c-di-GMP analogues have been identified 
that exhibit good binding affinity with the c-di-GMP specific riboswitches and can 
potentially be used to modulate bacterial physiology (Furukawa, Gu et al. 2012). 
 At the same time, pathogens that require opposing cyclic-di-GMP 
metabolizing enzymes at different phases of infection have been characterized; 
indicating that regulating the levels of this molecule can be used to control the 
phenotype of pathogens. In the case of Staphylococcus aureus, cyclic-di-GMP has 
been found to inhibit intercellular adhesive interactions in bovine and human isolates 
(including MRSA strains) (Karaolis, Rashid et al. 2005), rendering a potential use as a 
biofilm dispersal agent in medical devices such as enteral tubes. 
Study of the signaling pathways of this molecule and identification of 
receptors necessitates significant quantities of this molecule. Also, in vitro studies 
have shown that cyclic-di-GMP is capable of inhibiting growth factor induced 
proliferation of human colon cancer cells (Karaolis, Cheng et al. 2005). Cytotoxicity 
studies of this molecule have been shown to be non-lethal at biologically relevant 




with a murine model of pneumonia, cyclic-di-GMP has been shown to stimulate 
innate immune response of the host against bacterial infection (Karaolis, Newstead et 
al. 2007). It has also been shown that in c-di-GMP controls the virulence of 
Staphylococcus aureus in a dose dependent manner in a mouse model of mastitis 
infection (Brouillette, Hyodo et al. 2005). The immunomodulatory properties of c-di-
GMP open up the possibility of using it as a vaccine adjuvant. The STING receptor in 
mammals responds to cyclic-di-GMP causing production of cytokines to eliminate the 
pathogen (Burdette, Monroe et al. 2011). The STING receptor is shown to be 
activated by the pattern recognition receptor, DDX41 helicase that sensed both c-di-
AMP and c-di-GMP (Parvatiyar, Zhang et al. 2012).   
Thus the need for cyclic-di-GMP is very important. Although this molecule is 
synthesized in bacteria, low intracellular levels render it impossible to isolate this 
molecule from bacteria. This molecule is either chemically synthesized or 
enzymatically produced. The chemical method is not cost effective. Since currently 
used bacterial diguanylate cyclases have poor thermostability and yield low amounts 
of cyclic-di-GMP due to feedback inhibition, a diguanylate cyclase from Thermotoga 
maritima was engineered with an I site mutation to enable commercial scale synthesis 
of cyclic-di-GMP. This enzyme, with a single mutation at the I site (R158A), has been 
patented by our collaborator.  
Since the structure of a hyperthermophilic GGDEF domain is unknown, 
structural characterization of this domain and comparison with mesophilic 
homologous structures can help in understanding the mechanism of thermostability, 
providing important clues for rational design of thermostable proteins. Also, we aim 
to address the mechanism of inhibition followed in GGDEF domains with a 




addition to inhibition by domain immobilization. Since our study involves the 
regulation mechanisn of just the GGDEF domain, this would help in establishing a 
general mechanism of regulation for DGCs that are devoid of other regulatory 
domains. Our study involves the structural characterization of the WT GGDEF 
domain and the I site mutant with a view of understanding its thermostability and the 
mechanism of feedback inhibition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
